Hong Kong Commercial Services Stock News

Redco Healthy Living Company Limited ( HKG:2370 ) shares have continued their recent momentum with a 56% gain in the...

Even though Pangaea Connectivity Technology Limited ( HKG:1473 ) posted strong earnings, investors appeared to be...

When close to half the companies in Hong Kong have price-to-earnings ratios (or "P/E's") above 12x, you may consider...

The Raily Aesthetic Medicine International Holdings Limited ( HKG:2135 ) share price has done very well over the last...

Scholar Education Group ( HKG:1769 ) shareholders won't be pleased to see that the share price has had a very rough...

Key Insights Significant control over China Bohai Bank by private companies implies that the general public has more...

If you want to compound wealth in the stock market, you can do so by buying an index fund. But if you pick the right...

It is hard to get excited after looking at China Shenhua Energy's (HKG:1088) recent performance, when its stock has...

Key Insights Significant control over SIM Technology Group by retail investors implies that the general public has more...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Mobicon Group Limited ( HKG:1213 ) shares have continued their recent momentum with a 34% gain in the last month alone...

There wouldn't be many who think CHYY Development Group Limited's ( HKG:8128 ) price-to-earnings (or "P/E") ratio of...

Solid profit numbers didn't seem to be enough to please National Electronics Holdings Limited's ( HKG:213...

China HK Power Smart Energy Group Limited ( HKG:931 ) shares have continued their recent momentum with a 26% gain in...

Key Insights Significant control over Oshidori International Holdings by retail investors implies that the general...

The board of Pokfulam Development Company Limited ( HKG:225 ) has announced that it will pay a dividend on the 6th of...

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Vitasoy International Holdings Limited's ( HKG:345 ) solid earnings announcement recently didn't do much to the stock...

Insiders who bought Daido Group Limited ( HKG:544 ) in the last 12 months may probably not pay attention to the stock's...

Shareholders appeared unconcerned with Sa Sa International Holdings Limited's ( HKG:178 ) lackluster earnings report...

China Coal Energy (SEHK:1898) just released its November 2025 operations update, showing coal production and sales under pressure, while ammonium nitrate output and sales jumped sharply, hinting at a quiet shift in the earnings mix. See our latest analysis for China Coal Energy. The stock has cooled off in recent weeks, with a 1 month share price return of minus 9.05 percent. However, momentum over the year still looks constructive, supported by a 1 year total shareholder return of 21.34...

Innovent Biologics (SEHK:1801) just hit a scientific milestone, with two Phase 3 trials of its dual GCG/GLP-1 drug mazdutide published back to back in Nature, sharpening the investment case around its diabetes franchise. See our latest analysis for Innovent Biologics. The latest Nature publications cap a run of positive catalysts, including NRDL additions and Hang Seng index inclusion. This comes even as the 30 day share price return of minus 7.1% contrasts with a powerful 1 year total...

Dekon Food and Agriculture Group reported that in November 2025 it sold 1,065,780 pigs, generating RMB 1,591.58 million in unaudited sales revenue. For the eleven months to November 30, 2025, the company sold 9,718,310 pigs and recorded RMB 17,524.08 million in unaudited sales, offering a detailed snapshot of its operating scale. We’ll now examine how this reported eleven‑month sales volume and revenue run-rate shapes Dekon Food and Agriculture Group’s investment narrative. Outshine the...

Alphamab Oncology recently reported that the Center for Drug Evaluation of China’s NMPA has accepted its IND application for JSKN027, an independently developed bispecific antibody-drug conjugate targeting PD-L1 and VEGFR2, paving the way for a Phase I trial in advanced solid tumors. This milestone highlights Alphamab Oncology’s push into next-generation bispecific ADCs that combine immune checkpoint blockade and anti-angiogenic mechanisms within a single molecule. We’ll now examine how the...